Treatment-emergent CNS symptoms following triptan therapy are part of the attack.
If treatment-emergent central nervous system (CNS) symptoms following triptan therapy represent direct pharmacological effects of the drug, they should occur independent of response to active drug. However, if they represent unmasking of neurological symptoms of the migraine attack after pain is relieved, they should be more common in responders both to active drug and to placebo. To explore this issue, we evaluated the relationship between the CNS adverse events and treatment response following triptan or placebo treatment. We used pooled data from seven double-blind, placebo-controlled trials involving eletriptan 20 mg (E20, n = 402), eletriptan 40 mg (E40, n = 1870), eletriptan 80 mg (E80, n = 1393), sumatriptan 100 mg (S100, n = 275) and placebo (Pbo, n = 1024). Somnolence was more prevalent among 2 h headache responders than non-responders for all treatments, including E80 (8.8% vs. 5.0%; P < 0.05), E40 (6.4% vs. 5.0%; NS), E20 (4.0% vs. 2.0%; NS), S100 (4.7% vs. 3.2%; NS) and Pbo (7.6% vs. 3.0%; P < 0.05). Similarly, the incidence of asthenia was higher among patients who responded to treatment compared with those who did not respond to E80 (15.2% vs. 7.8%; P < 0.05), E40 (6.5% vs. 3.6%; P < 0.05), E20 (6.5% vs. 1.0%; P < 0.05), S100 (10.1% vs. 4.7%; NS) and Pbo (4.4% vs. 2.7%; NS). The generally higher rates of somnolence and asthenia in patients who respond to treatment suggests that these treatment-emergent neurological symptoms may represent the unmasking of CNS symptoms associated with the natural resolution of a migraine attack, rather than simply representing drug-related side-effects. The rate of somnolence in placebo responders is comparable to that in responders to E40 and E80, indicating that somnolence is related, at least in some important part, to headache relief and not treatment.
Goadsby
P J
PJ
Institute of Neurology, London, UK. peterg@ion.ucl.ac.uk
Dodick
D W
DW
Almas
M
M
Diener
H-C
HC
Tfelt-Hansen
P
P
Lipton
R B
RB
Parsons
B
B
D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects; D001247:Asthenia / Q000139:chemically induced* / Q000453:epidemiology; D002493:Central Nervous System Diseases / Q000139:chemically induced* / Q000453:epidemiology; D015331:Cohort Studies; D006970:Disorders of Excessive Somnolence / Q000139:chemically induced* / Q000453:epidemiology; D004311:Double-Blind Method; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy / Q000453:epidemiology; D015337:Multicenter Studies as Topic; D015990:Placebo Effect; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D014363:Tryptamines / Q000009:adverse effects* / Q000627:therapeutic use
D000700:Analgesics; D014363:Tryptamines